MetaCap

IRulya Therapeutics (IRLA) Short Interest

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Latest short interest · Oct 30, 2026

Change vs prior
-17.4%
Avg. daily volume
112.69K
Prior report
154.74K

IRulya Therapeutics short interest analysis

As of the Oct 30, 2026 settlement date, 127,816 IRLA shares were sold short, equal to 1.18% of IRulya Therapeutics's shares outstanding. That is down 17.4% from the previous report of 154.74K shares. With average daily volume of 112.69K shares, it would take about 1.1 trading days for short sellers to buy back their positions, which is low by typical standards.

Summary generated from market data by MetaCap's automated system. Methodology

IRLA short interest history

IRulya Therapeutics short interest by settlement date
SettlementShort InterestChange% Shares Out.Days to Cover
Oct 30, 2026127,816-17.4%1.18%1.13
Oct 15, 2026154,736+158.1%1.43%3.30

Days to cover = shares short ÷ average daily volume. Short percent uses total shares outstanding as the denominator, which is slightly lower than a float-based figure.

Frequently asked questions

What is IRulya Therapeutics's short interest?

IRLA short interest was 127,816 shares as of Oct 30, 2026, or 1.18% of shares outstanding, down 17.4% from the prior report.

What is IRLA's days to cover?

IRLA's days-to-cover (short interest ratio) is 1.13, meaning short sellers would need about 1.1 days of average trading volume to close their positions.

How often is short interest reported?

FINRA requires brokers to report short positions twice a month, as of mid-month and month-end settlement dates. The data is published about a week and a half after each settlement date, so it is always somewhat delayed.

Is high short interest bullish or bearish?

High short interest shows that many investors expect the price to fall, which is a bearish signal. It can also set up a short squeeze if the stock rises and short sellers rush to buy back shares. Neither outcome is guaranteed.

Related